中国医药
中國醫藥
중국의약
CHINA MEDICINE
2012年
2期
206-207
,共2页
罗顺文%许亚宏%赵启华%段志强%张波
囉順文%許亞宏%趙啟華%段誌彊%張波
라순문%허아굉%조계화%단지강%장파
盐酸坦洛新%双J管%IPSS评分
鹽痠坦洛新%雙J管%IPSS評分
염산탄락신%쌍J관%IPSS평분
Tamsulosin%Double-J stent%International prostate symptom score
目的 评估盐酸坦洛新缓释片改善留置双J管引起的并发症及患者生活质量的作用.方法 选取76例输尿管中下段结石患者,均行输尿管镜碎石术,术后留置双J管4周,按随机数字表法分为2组:观察组37例,出院后口服盐酸坦洛新缓释片,0.4 mg/(次·d),服用4周,而对照组(39例)未使用任何药物.所有患者拔管时行视觉模拟(VAS)评分、国际前列腺症状评分(IPSS)和生存质量调查(SF-36)问卷调查等.结果 所有患者均完成问卷调查.观察组患者躯体疼痛发生率、VAS评分及IPSS总分与对照组患者比较,差异均有统计学意义[( 17/37) 45.9%比(34/39) 87.2%;(3.7±0.8)分比(5.8 ± 1.2)分,(16.5±2.3)分比(30.2±5.3)分,均P<0.05];2组患者SF-36量表中各项指标中,社会职能和情感职能的组间差异无统计学意义[(88±12)分比(83±10)分;(82±11)分比(77±12)分,均P>0.05].本研究中2组患者未见明显药物不良反应.结论 酸坦洛新缓释片可以改善留置双J管引起的相关并发症,提高患者生活质量,且无严重副作用.
目的 評估鹽痠坦洛新緩釋片改善留置雙J管引起的併髮癥及患者生活質量的作用.方法 選取76例輸尿管中下段結石患者,均行輸尿管鏡碎石術,術後留置雙J管4週,按隨機數字錶法分為2組:觀察組37例,齣院後口服鹽痠坦洛新緩釋片,0.4 mg/(次·d),服用4週,而對照組(39例)未使用任何藥物.所有患者拔管時行視覺模擬(VAS)評分、國際前列腺癥狀評分(IPSS)和生存質量調查(SF-36)問捲調查等.結果 所有患者均完成問捲調查.觀察組患者軀體疼痛髮生率、VAS評分及IPSS總分與對照組患者比較,差異均有統計學意義[( 17/37) 45.9%比(34/39) 87.2%;(3.7±0.8)分比(5.8 ± 1.2)分,(16.5±2.3)分比(30.2±5.3)分,均P<0.05];2組患者SF-36量錶中各項指標中,社會職能和情感職能的組間差異無統計學意義[(88±12)分比(83±10)分;(82±11)分比(77±12)分,均P>0.05].本研究中2組患者未見明顯藥物不良反應.結論 痠坦洛新緩釋片可以改善留置雙J管引起的相關併髮癥,提高患者生活質量,且無嚴重副作用.
목적 평고염산탄락신완석편개선류치쌍J관인기적병발증급환자생활질량적작용.방법 선취76례수뇨관중하단결석환자,균행수뇨관경쇄석술,술후류치쌍J관4주,안수궤수자표법분위2조:관찰조37례,출원후구복염산탄락신완석편,0.4 mg/(차·d),복용4주,이대조조(39례)미사용임하약물.소유환자발관시행시각모의(VAS)평분、국제전렬선증상평분(IPSS)화생존질량조사(SF-36)문권조사등.결과 소유환자균완성문권조사.관찰조환자구체동통발생솔、VAS평분급IPSS총분여대조조환자비교,차이균유통계학의의[( 17/37) 45.9%비(34/39) 87.2%;(3.7±0.8)분비(5.8 ± 1.2)분,(16.5±2.3)분비(30.2±5.3)분,균P<0.05];2조환자SF-36량표중각항지표중,사회직능화정감직능적조간차이무통계학의의[(88±12)분비(83±10)분;(82±11)분비(77±12)분,균P>0.05].본연구중2조환자미견명현약물불량반응.결론 산탄락신완석편가이개선류치쌍J관인기적상관병발증,제고환자생활질량,차무엄중부작용.
Objective To evaluate the efficacy of tamsulosin in relieving stent-related symptoms and improving quality of life in patients with in-dwelling double-J ureteral stents.Methods Seventy-six patients (57 males and 19 females) with ureteral stent placement following ureteroscopy lithoclasty of calculus in the middle or lower piece of ureter were prospectively randomized into two groups.Group Ⅰ (37 patients) received 0.4 mg tamsulosin for 4 weeks ; group Ⅱ (39 cases) was a non-placebo and non-treatment control.All patients had questionnaires of the Visual Analogue Scale(VAS) and the International Prostate Symptom Score (IPSS) and SF-36 at 4 weeks postoperatively.Results All patients completed the questionnaires.The rates of pain and VAS scores and IPSS scores were significantly different between the two groups (P < 0.01 ).The rates of pain:45.9% vs 87.2% ; VAS:( 3.7± 0.8 ) grades vs ( 5.8 ± 1.2 ) grades; total scores of IPSS:( 16.5 ± 2.3 ) grades vs ( 30.2 ± 5.3 ) grades.Among the eight domains of SF-36,only the domains of social function and emotional function had no significant differences:(88 ± 12) grades vs (83 ± 10) grades and (82 ± 11 )grades vs (77 ± 12) grades (P >0.05).No evident adverse reaction of the treatment was found.Conclusion Tamsulosin can improve both urinary symptoms and quality of life without causing serious side-effects.